32
Participants
Start Date
April 10, 2019
Primary Completion Date
January 27, 2023
Study Completion Date
January 27, 2023
Pegzilarginase
Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
Placebo
Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
Icahn School of Medicine at Mount Sinai, New York
Cohen Children's Medical Center (Northwell Health), Queens
University of Pittsburgh Medical Center, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Duke University Medical Center, Durham
Emory University, Atlanta
University of Florida College of Medicine, Gainesville
Vanderbilt University Medical Center, Nashville
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Harvey Pediatrics, Rogers
UT Southwestern Medical Center, Dallas
University of Texas Health Science Center Medical School at Houston, Houston
University of Utah Hospitals & Clinics, Salt Lake City
Children's Hospital of Orange County, Orange
Stanford University School of Medicine, Stanford
Seattle Children's Hospital, Seattle
LKH Bregenz, Bregenz
Medizinische Universität Innsbruck, Innsbruck
McGill University Health Center, Montreal
Hôpital Necker - Enfants Malades, Paris
Hopital des Enfants, Talence
Universitaetsklinikum Muenster, Münster
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz
Fondazione MBBM, Monza
Ospedale Pediatrico Bambino Gesù, Roma
Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino
Birmingham Children's Hospital, Birmingham
University Hospital of Wales, Cardiff
Great Ormond Street Hospital for Children, London
Willink Biochemical Genetics Unit, Manchester
Salford Royal, Salford
Lead Sponsor
Aeglea Biotherapeutics
INDUSTRY